Nifty 50
Tools & Calculators
Stocks
F&O
Mutual Funds
Sector: Pharmaceuticals & Biotechnology
|Small Cap
AMBALALSA
₹42.50
₹36.99
₹43.00
Data is not available
Markets Today
Historical Performance
As of 05-08-2026 04:43, Ambalal Sarabhai Enterprises Ltd. share price today is ₹0, with a change of ₹-37.26 (-100.00%) from the previous close of ₹37.26. The stock opened at ₹36.99 and traded between ₹36.99 and ₹43, with a total traded volume of 231669 shares. The company has a market capitalization of ₹285.5 Cr in the Pharmaceuticals & Biotechnology sector. while its 52-week high and low are ₹38.85 and ₹23.12, respectively.
Ambalal Sarabhai Enterprises Ltd. valuation metrics include a P/E ratio of 16, EPS of ₹2.32, and book value of ₹1.80. Profitability indicators show ROE of 11.24%. Ambalal Sarabhai Enterprises Ltd. has reported revenue of ₹202.27 Cr and net profit of ₹17.8 Cr.
Ambalal Sarabhai Enterprises Ltd. technical indicators include Day RSI at 72.69, Day MFI at 89.59, Day ADX at 32.21. Additional indicators include Commodity Channel Index (CCI) at 331.2 and Williams %R at -3.27. Momentum indicators show Day MACD at 0.61, Day MACD Signal Line at 0.06, DayATR at 2.02. Rate of Change indicators for Ambalal Sarabhai Enterprises Ltd. include ROC125 at 37.85 and ROC21 at 13.88.
Exponential moving averages include EMA5 at ₹34.5, EMA10 at ₹33.3, EMA12 at ₹33.1, EMA20 at ₹32.6, EMA26 at ₹32.5, EMA50 at ₹32.1, EMA100 at ₹31.4, EMA200 at ₹31.7. Simple moving averages include SMA5 at ₹33.5, SMA10 at ₹32.8, SMA20 at ₹32, SMA30 at ₹32, SMA50 at ₹32.6, SMA100 at ₹31.1, SMA150 at ₹29.8, SMA200 at ₹29.9.
Support levels for Ambalal Sarabhai are placed at First Support ₹34.35, Second Support ₹31.43, Third Support ₹29.86. Resistance levels are seen at First Resistance ₹38.84, Second Resistance ₹40.41, Third Resistance ₹43.33. Ambalal Sarabhai Enterprises Ltd. shareholding pattern shows promoter holding at 31.36%, FII holding at 0%, DII holding at 0%, public holding at 68.64%.
Indicator | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Total Revenue | 1.52 | 0 | 0.79 | 1.64 | 1.73 |
| Operating Expense | 2.87 | 0.94 | 2.42 | 2.82 | 3.43 |
| Operating Profit | -1.35 | -0.94 | -1.63 | -1.18 | -1.70 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Interest | 0.17 | 0.09 | 0.08 | 0.07 | 0.05 |
| Tax | -1.04 | -0.01 | 0 | 0 | -0.02 |
| Net Profit | 2.65 | 1.84 | -0.38 | 6.88 | -4.96 |
₹42.50
↗ Bullish Moving Average
16
↘ Bearish Moving Average
0
Ambalal Sarabhai Enterprises is part of India’s long-standing business landscape, with operations connected to pharmaceuticals, electronics, and engineering through its subsidiaries and investments. When analysts review the Ambalal Sarabhai share 2025-2026, they focus on assessing the value of its legacy assets along with its ongoing partnerships and business interests. Market participants often monitor the Ambalal Sarabhai live share price to stay informed about short-term movements that may arise from company developments or announcements. For those looking at longer holding periods, studying the Ambalal Sarabhai Share Trend helps in understanding how the company’s value has evolved over time. The Ambalal Sarabhai stock quote provides a quick snapshot of current market perception regarding its overall asset base and operations.
Investors regularly track the Ambalal Sarabhai share price to evaluate whether the combined value of its businesses and holdings is reflected in the market. The Ambalal Sarabhai market price is often compared with its historical book value to assess relative valuation. Observing the Ambalal Sarabhai live price is useful during periods of increased activity, especially when there are updates related to subsidiaries. Over time, the Ambalal Sarabhai market cap helps position the company among other holding entities and manufacturing-based firms. Monitoring the daily Ambalal Sarabhai stock price also provides a simple indication of how the company’s financial decisions and asset management are viewed by the market.
Ambalal Sarabhai Enterprises Limited traces its origins to the Sarabhai Group, one of India’s early industrial houses with a strong legacy in pharmaceuticals, chemicals, and engineering. The group played a significant role in India’s industrial and pharmaceutical development in the post-independence era.
Ambalal Sarabhai Enterprises Limited (ASE) emerged as part of the restructuring of the Sarabhai Group and has evolved into a diversified company with interests in pharmaceuticals, chemicals, and electronics.
The company is headquartered in Ahmedabad, Gujarat. Over time, the business has transitioned from a large-scale manufacturing-led model to a more focused structure comprising operating subsidiaries, joint ventures, and niche manufacturing businesses.
Ambalal Sarabhai Enterprises Limited operates through multiple subsidiaries and divisions, focusing on niche and specialized product segments:
Pharmaceuticals and APIs:
Through subsidiaries such as Sarabhai Chemicals, the group manufactures Active Pharmaceutical Ingredients (APIs) and formulations catering to domestic and international markets.
Specialty Chemicals:
The company is engaged in manufacturing fine chemicals and specialty chemical products used in pharmaceutical and industrial applications.
Electronics and Engineering:
Through its electronics division, including Synbiotics Limited, the group operates in niche electronic and engineering product segments.
The company structures its operations through subsidiaries to manage distinct business lines and associated risks.
Ambalal Sarabhai Enterprises Limited operates a diversified revenue model combining manufacturing income and investment-linked earnings.
Key revenue streams include:
Pharmaceutical and Chemical Sales:
Revenue generated through subsidiaries engaged in API manufacturing, formulations, and specialty chemicals.
Dividend and Investment Income:
Income from investments, joint ventures, and group companies contributes to overall cash flows.
Other Operating Income:
Includes income from services, asset utilization, and other business activities across subsidiaries.
The company’s revenue profile reflects a mix of operating business performance and returns from investments and restructuring initiatives.
Ambalal Sarabhai Enterprises Limited has a geographically concentrated base in western India with broader market reach:
Headquarters:
Ahmedabad, Gujarat
Manufacturing and Operations:
Primarily located in Gujarat, leveraging the state’s established industrial ecosystem
Market Presence:
Domestic operations supported by exports through pharmaceutical and chemical businesses
The company continues to leverage its legacy infrastructure and industrial base in Gujarat for its operations.
Some of the Key leaders as of Marcj 2026 are
The Indian pharmaceutical and specialty chemical sectors thrive on a rapidly growing global demand for affordable alternatives. A deeper look at the industrial outlook shows a clear pivot towards companies that can provide secure, China-independent supply chains. Companies with established manufacturing footprints and FDA compliance benefit immensely from this macro shift. Adapting to fast-changing environmental regulations remains the biggest hurdle for legacy chemical firms. For investors, seeing a holding company successfully revive an old manufacturing asset strongly influences the Ambalal Sarabhai share price. In conclusion, the ability to navigate complex regulatory turnarounds directly impacts the Ambalal Sarabhai stock price.
Ambalal Sarabhai Enterprises is listed on the Bombay Stock Exchange (BSE) under Scrip Code: 500008. Investors and analysts refer to exchange data to track the Ambalal Sarabhai share price and understand trading patterns. Market participants also review trading volumes to identify periods of increased buying or selling interest. The company is not included in major benchmark indices such as the Nifty 50, Sensex, Nifty Midcap 100, or Nifty Smallcap 100 due to its classification as a micro-cap entity with a holding company structure. Despite this, consistent observation of the Ambalal Sarabhai share price helps reflect investor interest in companies with diversified assets and restructuring potential.
The Ambalal Sarabhai performance has been influenced by internal restructuring activities, asset sales, and developments within its subsidiaries. Historical price trends show that changes in the Ambalal Sarabhai stock price often correspond with the resolution of financial or legal matters and updates on business operations. Reviewing past data helps explain how the company’s valuation has responded to specific events over time. The Ambalal Sarabhai share price may experience periods of volatility, which traders monitor using technical tools and price charts. The Ambalal Sarabhai live price is especially relevant for those making short-term decisions. Over longer durations, the movement of the Ambalal Sarabhai stock price is linked to the performance of its active investments and joint ventures.
The investment approach for Ambalal Sarabhai Enterprises often involves assessing the combined value of its assets relative to its market valuation. Investors examine the Ambalal Sarabhai share price to determine whether the company is trading below its estimated asset value. Monitoring management decisions, including the treatment of minority shareholders, is an important part of this evaluation. The Ambalal Sarabhai P/E ratio is considered along with other measures, though price-to-book value is frequently used due to the nature of its holdings. Earnings contributions from its pharmaceutical-related businesses support continued interest from certain investor groups. The Ambalal Sarabhai share price is also followed during intraday sessions by traders who track price movements and liquidity.
Ambalal Sarabhai Enterprises operates as a diversified holding entity with connections to multiple sectors, which distinguishes it from companies focused on a single industry. Its subsidiaries contribute to areas such as chemicals and pharmaceuticals, where it competes with other firms for business opportunities, including export markets. A structured comparison with peers shows that the company’s value is influenced by its asset base as well as the progress of its restructuring process. The Ambalal Sarabhai share price often reflects overall market sentiment toward companies with similar structures. Evaluations of strengths and risks highlight asset backing as a key factor, while delays in restructuring or legal matters may affect performance.
Summary
Ambalal Sarabhai Enterprises represents a combination of legacy assets and ongoing business interests within a listed holding company structure. The Ambalal Sarabhai share price, along with indicators such as market cap and stock price trends, helps investors understand how the market values its diversified portfolio. Its presence on the BSE provides transparency in pricing and trading activity, even though it is not part of major indices. Reviewing historical performance, valuation metrics, and sector positioning offers a clearer picture of its role in the market. Regular tracking of the Ambalal Sarabhai stock price supports informed observation of its financial and operational developments.
| Held By | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Promoter | 31.4 | 31.4 | 31.4 | 31.4 | 31.4 | 31.4 |
| FII | 0.4 | 0.4 | 0.3 | 0.3 | 0 | 0 |
| DII | 0.1 | 0 | 0 | 0 | 0 | 0 |
| Public | 68.2 | 68.3 | 68.3 | 68.3 | 68.6 | 68.6 |
| Period | Combined Delivery Volume | NSE+BSE Traded Volume Avg | Daily Avg Delivery Volume % |
|---|---|---|---|
| Day | 2.84 L | 5.25 L | 54.09% |
| Week | 1.7 L | 2.83 L | 60.04% |
| 1 Month | 82.98 K | 1.27 L | 65.28% |
| 6 Month | 85.5 K | 1.25 L | 68.38% |
High DVM Mid and Small Caps (subscription)
Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Undervalued Growth Stocks
Strong Momentum: Price above short, medium and long term moving averages
Jim Slater's Zulu Principle (Discover Growth Stocks)
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Effectively using its capital to generate profit - RoCE improving in last 2 years
Growth in Net Profit with increasing Profit Margin (QoQ)
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Increasing Revenue every quarter for the past 3 quarters
Increasing profits every quarter for the past 2 quarters
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Near 52 Week High
RSI indicating price strength
High Volume, High Gain
Biggest Price Gainers from Open
Top Gainers
High Volume, High Gain
Volume Shockers
Stocks Outperforming their Industry Price Change in the Quarter
Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| No Record Found | ||||
Financials | ||||||
|---|---|---|---|---|---|---|
| Price (₹) | ₹156 | ₹41.20 | ₹530 | ₹180.90 | ₹283.50 | ₹25 |
| % Change | -1.27% | 0.00% | -4.43% | 0.00% | -4.87% | 0.00% |
| Revenue TTM (₹ Cr) | - | - | - | - | - | ₹1.27 |
| Net Profit TTM (₹ Cr) | - | - | - | - | - | ₹-0.25 |
| PE TTM | 12.20 | 9.60 | - | 12.20 | 42.60 | -59.20 |
| 1 Year Return | 13.67 | 41.47 | 455.56 | |||
| ROCE | 34.19 | - | 3.56 | - | - | - |
Vivimed Labs Ltd.
₹ 5.09
+2.21%
Curis Lifesciences Ltd.
₹ 110.00
-0.09%
Aptus Pharma Ltd.
₹ 300.00
+1.52%
Amanta Healthcare Ltd.
₹ 169.75
-1.36%
Anlon Healthcare Ltd.
₹ 14.60
-0.75%
Medistep Healthcare Ltd.
₹ 19.50
+1.56%
Patel Chem Specialities Ltd.
₹ 92.00
+0.24%
Asston Pharmaceuticals Ltd.
₹ 76.00
+8.65%
Influx Healthtech Ltd.
₹ 294.90
+2.17%
Medicamen Organics Ltd.
₹ 29.85
+4.74%
Amrutanjan Health Care Ltd.
₹ 515.05
-1.18%
Astonea Labs Ltd.
₹ 270.00
-1.37%
Amwill Health Care Ltd.
₹ 43.24
+0.56%
Valiant Laboratories Ltd.
₹ 62.18
+0.71%
Shelter Pharma Ltd.
₹ 26.53
+0.00%
Trident Lifeline Ltd.
₹ 255.05
-3.41%
Dipna Pharmachem Ltd.
₹ 4.20
-14.81%
Achyut Healthcare Ltd.
₹ 7.12
+4.71%
Sigachi Industries Ltd.
₹ 26.28
-1.24%
Windlas Biotech Ltd.
₹ 857.00
-1.24%
Vineet Laboratories Ltd.
₹ 39.75
+3.65%
Chandra Bhagat Pharma Ltd.
₹ 39.36
+4.96%
Solara Active Pharma Sciences Ltd.
₹ 520.10
+0.82%
By signing up I certify terms, conditions & privacy policy